By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Calcium channel blocking agents > Clevidipine > Clevidipine Dosage
Calcium channel blocking agents
https://themeditary.com/dosage-information/clevidipine-dosage-8999.html

Clevidipine Dosage

Drug Detail:Clevidipine (Clevidipine [ kle-vid-a-peen ])

Drug Class: Calcium channel blocking agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Hypertension

Initial dose: 1 to 2 mg/hour IV infusion

Dose titration: Dose may be doubled at short (90 second) intervals initially. As blood pressure approaches goal, dose increases should be less than doubling and intervals between dose adjustments should increase to every 5 to 10 minutes. An increase of approximately 1 to 2 mg/hour generally produces an additional 2 to 4 mmHg decrease in systolic pressure.

Maintenance dose: The desired therapeutic response for most patients occurs at doses of 4 to 6 mg/hour. Patients with severe hypertension may require doses up to 32 mg/hour.

Maximum dose: Most patients were treated with maximum doses of 16 mg/hour or less; however, there is limited short-term experience with doses up to 32 mg/hour. Due to lipid load restrictions, no more than 1000 mL (or an average of 21 mg/hour) is recommended per 24-hour period.

Duration of therapy: There is little experience with infusion durations beyond 72 hours at any dose.

Transition to an oral antihypertensive agent: Discontinue this drug or titrate downward while appropriate oral treatment is established.

Use: Reduction of blood pressure when oral treatment is not feasible or not desirable.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS:

  • Allergy to soybeans, soy products, eggs, or egg products
  • Defective lipid metabolism (e.g., pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia)
  • Severe aortic stenosis

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Use an infusion device that allows for calibrated infusion rates.
  • Commercially-available standard plastic cannulae may be used.
  • Administer via a central or peripheral line.

Storage requirements:
  • Refrigerate at 2C to 8C (36F to 46F). Do not freeze.
  • Vials in cartons may be transferred to 25C (77F) for a period not to exceed 2 months. Do not return to refrigeration after beginning room temperature storage.
  • Protect from light.
  • Discard any unused product within 12 hours of stopper puncture.

Reconstitution/preparation techniques:
  • Do not dilute.
  • Invert vial gently several times before use to ensure uniformity.

IV compatibility:
  • Do not administer in the same line as other medications.
  • May be administered with the following: Water for Injection, USP; Sodium Chloride (0.9%) Injection, USP; Dextrose (5%) Injection, USP; Dextrose (5%) in Sodium Chloride (0.9%) Injection, USP; Dextrose (5%) in Ringer's Lactate Injection, USP; Lactated Ringer's Injection, USP; 10% amino acid.

Monitoring:
  • Cardiovascular: Blood pressure and heart rate (continuously during infusion and until vital signs stabilize; for patients who receive prolonged infusions and are not transitioned to other antihypertensive agents, monitor for at least 8 hours post-infusion for the possibility of rebound hypertension)
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by